Skip to NavigationSkip to content

vitamin K antagonist

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana

Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial fibrillation patients undergoing catheter ablation.

The study showed the uninterrupted anticoagulation regimen with 60mg edoxaban versus uninterrupted vitamin K antagonists, in patients undergoing catheter ablation resulted in low event rates for both thromboembolic and bleeding events.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches